Double-blind, placebo-controlled study with
reboxetine in inpatients with severe major depressive disorder
Versiani M, Amin M, Chouinard G
Federal University,
Rio de Janeiro, Ipanema, Brazil.
J Clin Psychopharmacol 2000 Feb; 20(1):28-34
ABSTRACT
The efficacy and tolerability of reboxetine, a unique selective noradrenaline reuptake inhibitor, were compared with those of placebo in a 6-week, randomized, double-blind study of hospitalized patients with a DSM-III-R diagnosis of major depressive disorder. Fifty-two patients (25 in the placebo group, 27 in the reboxetine group) were included in the efficacy analysis. Sixteen (64%) of those in the placebo group and four (15%) in the reboxetine group were withdrawn during the study because of lack of efficacy. Improvement in the mean Hamilton Rating Scale for Depression (HAM-D) total score at last assessment was significantly greater in the reboxetine group than in the placebo group (p < 0.001). Similarly, the response rate to treatment, defined as > or =50% reduction in HAM-D total score, was 74% for patients who received reboxetine compared with 20% for those who received placebo (p < 0.001). A significantly greater response with reboxetine than with placebo was seen as early as day 10 of treatment (p = 0.006). The therapeutic efficacy of reboxetine was substantiated by improvement in mean scores on the Zung Self-Rating Scale and on the Clinical Global Impression Severity of Illness and Global Improvement scales. Reboxetine was well tolerated, and only one patient in each group withdrew because of adverse events. Dry mouth, insomnia, blurred vision, sweating, and constipation were recorded more frequently in the reboxetine group than in the placebo group. There was a tendency toward orthostatic changes in the systolic blood pressure, but this was not clinically significant. This study demonstrated that reboxetine is significantly more effective than placebo in the treatment of hospitalized patients with severe major depressive disorder and is well tolerated.
-
Reboxetine research
/ abstracts
1. Reboxetine
role in antidepressant therapy
2. Reboxetine
efficacy and tolerability
3. Reboxetine
clinical pharmacologic profile
4. Reboxetine
Inhibiting noradrenaline
and serotonin reuptake
5. Reboxetine
and depression in the elderly
6. Reboxetine
with severe major depressive disorder
7. Reboxetine
clinical efficacy in major depression
8. Reboxetine
tolerability and safety for major depression
9. Reboxetine
comparison with fluoxetine
10. Reboxetine
versus fluoxetine, impact on social functioning
11. Reboxetine versus
fluoxetine, differential effects
12. Reboxetine
prevents relapse in major depression
13. Reboxetine
efficacy compared with imipramine
14. Noradrenaline
reuptake inhibition
15. Antidepressants
noradrenergic versus serotonergic
16. Reboxetine
in the treatment of bulimia
17. Reboxetine
hemodynamic effects in healthy males
18. Reboxetine
effects of antidepressant therapy
19. Reboxetine
place in antidepressant therapy
20. Reboxetine
stimulant effects in patients with narcolepsy
21. Reboxetine
selective noradrenaline reuptake inhibitor (NARI)
